Delving into the Latest Updates on Benzo[a]pyrene with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

3,4-Benzopyrene

Target-

Action-

Mechanism-

Therapeutic Areas

Immune System DiseasesRespiratory DiseasesOther Diseases

Active Indication-

Inactive Indication

Environmental IllnessFamilial Primary Pulmonary Hypertension

Originator Organization

National Institute of Health Sciences

Active Organization-

Inactive Organization

National Institute of Health Sciences

Drug Highest PhasePendingEarly Phase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC20H12

InChIKeyFMMWHPNWAFZXNH-UHFFFAOYSA-N

CAS Registry50-32-8

Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone, following 7 days' consumption of Brussels sprouts, and following 7 days' consumption of a supplement containing 3,3'-diindolylmethane (DIM).

Start Date24 Jan 2019

Sponsor / Collaborator

Oregon State University

[+2]

NCT03631667

/ CompletedEarly Phase 1IIT

Ultralow Dose PAH Binary Mixture Study

Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following a 50 ng dose (5.4 nCi) alone or with 1250 ng phenanthrene.

Start Date01 Oct 2018

Sponsor / Collaborator

Oregon State University

[+2]

NCT03318978

/ CompletedEarly Phase 1IIT

Benzo[a]Pyrene Ultralow Dose-Response Study

Evaluation of the pharmacokinetics for [14C]-benzo[a]pyrene ([14C]-BaP) and metabolites in plasma and urine over 48 hours following 4 oral doses of 25, 50, 10 and 250 ng (2.7-27 nCi).

Start Date17 Apr 2018

Sponsor / Collaborator

Oregon State University

[+2]

100 Clinical Results associated with Benzo[a]pyrene

Login to view more data

100 Translational Medicine associated with Benzo[a]pyrene

Login to view more data

100 Patents (Medical) associated with Benzo[a]pyrene

Login to view more data

45,888

Literatures (Medical) associated with Benzo[a]pyrene

03 Apr 2025·Environmental Technology

Enzymatic bioremediation of polycyclic aromatic hydrocarbons (PAHs) in contaminated soil: a study on the recombinant laccase TVL

Article

Author: Gao, Dawen ; Du, Xuran ; Chen, Guanyu ; Liang, Hong ; Li, Ming ; Wang, Litao ; Liu, Ye ; Lai, Weijian

Polycyclic aromatic hydrocarbons (PAHs) are pervasive and persistent pollutants in contaminated soil, posing a severe health and environmental threat. Enzymatic bioremediation presents a viable solution for the remediation of PAH-contaminated soil. In this study, a recombinant laccase with the encoding gene originating from Trametes villosa and recombinantly expressed in Aspergillus oryzae, designated as TVL, was discovered to possess strong PAH reduction capabilities. The specific enzyme activity of TVL was 73485 and 5102 LAMU/g enzyme protein at pH 5.0/7.0 and 37°C. Furthermore, it exhibited significant benzo[a]pyrene degradation, with 100% and 90.48% degradation at pH 5.0/7.0 after 24 h in the liquid phase. The degradation process of benzo[a]pyrene in soil was thoroughly investigated. Optimal conditions were identified as 15 mg/g NK-BSoil-3 and 1.35 mg/g HBT, resulting in a removal rate of 37.54% within 7 days when 0.01 U/g of TVL was applied. The potential mechanisms were investigated using molecular docking simulation. The binding energy between benzo[a]pyrene and TVL protein is notably robust, suggesting a higher propensity for enzyme binding. The TVL protein pocket contains nine amino acids that can interact most strongly with benzo[a]pyrene. Consequently, the recombinant laccase TVL holds considerable practical significance in bioremediation.

01 Apr 2025·Journal of Hazardous Materials

Benzo[a]pyrene exposure and incident risks of digestive system cancers: Insights from nested case-control studies and adverse outcome pathway network analysis

Article

Author: You, Yingqian ; Guan, Xin ; Zhao, Hui ; Bai, Yansen ; Guo, Huan ; Wang, Yuxi ; Fu, Ming ; Wang, Chenming ; Zhang, Yichi ; Chen, Shengli ; Fu, Ye ; Xiao, Yang ; Hong, Shiru ; Zhou, Yuhan

Benzo[a]pyrene (B[a]P) is a recognized carcinogen for lung cancer, but its associations with digestive system cancers (DSCs) remain unclear and the common carcinogenic mechanisms are not fully understood. We conducted five nested case-control studies within the Dongfeng-Tongji cohort, including esophageal (EC, n = 58), gastric (GC, n = 103), colorectal (CRC, n = 220), hepatic (HC, n = 117), and pancreatic cancers (PC, n = 45). For each case, two sex and age ( ± 5 years) matched healthy controls were selected. We observed significant J-shaped associations between plasma concentrations of benzo[a]pyrene diol epoxide-albumin (BPDE-Alb) adducts and five DSCs (all P for non-linear <0.05). The subjects with high BPDE-Alb exposure exhibited a separate 2.19, 2.14, 1.67, 2.40, and 1.78-fold incident risks of EC, GC, CRC, HC, and PC (95% CI: 1.00-4.83, 1.24-3.67, 1.15-2.43, 1.48-3.90, and 0.71-4.47, respectively) than those with low exposure. Furthermore, the adverse outcome pathway (AOP) network indicated five molecular initiation events and 18 subsequent key events, particularly, the alterations in receptors of AhR, EGFR accompanied by regulations of cell proliferation and apoptosis pathways (e.g., PI3K-Akt, TNF signaling) may facilitate common carcinogenic processes. Our findings revealed the positive associations of B[a]P exposure with five DSCs, and the dysregulation of proliferation and apoptosis may initiate B[a]P-induced cancer development.

01 Mar 2025·Environmental Pollution

Abiotic and biotic dissipation in natural attenuation of phenanthrene and benzo[a]pyrene: A systematic quantification study in contrasting soils

Article

Author: Lai, Xinyi ; Kong, Yi ; Cui, Xinyi ; Zhang, Qian ; Wu, Bang

Natural attenuation represents a significant ecosystem function for mitigating the quantity and toxicity of polycyclic aromatic hydrocarbons (PAHs) through both abiotic and biotic dissipation processes. This study systematically investigated abiotic and biotic dissipation of phenanthrene (Phe) and benzo[a]pyrene (BaP) in four soils over 360 days, using CSIA to quantitatively analyze δ¹³C changes and demonstrate biodegradation. The results indicated that extractable Phe was primarily attenuated via biodegradation (65% - 81%), as revealed by CSIA, with the δ¹³C changes ranging from 2.06‰ to 4.20‰ across the four soil types. Only 17% -27% of Phe dissipated by forming Type II non-extractable residues (NERs), while its Type I NERs remained available for microbial utilization. Notably, the microbial genera Gemmatimonas and Sphingomonas emerged as key contributors to the biotic dissipation of Phe. Conversely, extractable BaP was predominantly attenuated through abiotic process (35% - 52%), particularly via the formation of Type I and Type II NERs, with a smaller fraction (6% - 17%) undergoing biotic dissipation. Although the changes in δ¹³C values for BaP were only 0.76‰ -1.06‰, the significant changes (p<0.05) supported the microbial degradation of BaP. Additionally, soil organic matter and pH influenced the extractable and residual Phe, whereas soil electrical conductivity and texture primarily affected BaP rather than Phe. These findings underscore the multiple dissipation mechanisms involved in the natural attenuation of PAHs in soils and offer valuable quantitative data for remediation strategies of PAHs-contaminated soils.

100 Deals associated with Benzo[a]pyrene

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Familial Primary Pulmonary Hypertension	Phase 1	United States	National Institute of Health Sciences	01 Oct 2018
Environmental Illness	Phase 1	United States	National Institute of Health Sciences	17 Apr 2018